Cardiol Therapeutics Inc Class A has seen notable movements this week, with a 7.32% increase in stock price.
Cardiol Therapeutics Inc Class A (CRDL.TO) has made headlines recently, particularly with a week that has seen a positive uptick in stock performance. This week, shares closed at C$1.92, marking a 7.32% increase. Investors are keenly interested in the company’s progress in the healthcare sector, especially in light of recent publications and presentations regarding its product developments.
Advertisement
Earn cash back with a smarter spending account
Open a KOHO account and start earning on everyday purchases — no annual fee on the base plan.
Cardiol Therapeutics Inc Class A
CRDL.TO
CRDL.TO
Cardiol Therapeutics Inc Class A
WealthAwesomeMarket cap
$202.88M
52W high
$2.33
52W low
$1.23
1W change
+7.32%
Beta
0.51
Analyst Price Targets
Based on analyst covering CRDL
Wall Street analysts forecast CRDL stock price to rise 240.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+240.9% Upside
Current Price
C$1.76
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CRDL's historical volatility
30-Day Vol
55.4%
Annualized
90-Day Vol
59.6%
Annualized
Trend (90d)
-14.1%
Annualized drift
90d Mean
C$1.67
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.73 | C$1.43 – C$2.10 |
| 60 trading days | C$1.70 | C$1.30 – C$2.23 |
| 90 trading days | C$1.67 | C$1.20 – C$2.33 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: With a year-to-date increase of 29.41%, Cardiol Therapeutics is gaining attention, particularly following the recent publication of its Phase II study results. Investors may find the stock's technical indicators and analyst targets noteworthy.
C$1.92 closing price with a 7.32% weekly increase.
The stock has seen a significant increase in volume, trading 1.55 times its 20-day average, indicating heightened investor interest.
Bull case
The positive sentiment around Cardiol Therapeutics is bolstered by the recent release of its Phase II MAvERIC study results, which showed significant effectiveness in treating recurrent pericarditis. The company’s involvement in key industry events could further enhance its visibility and attract more investor interest.
Bear case
Despite the encouraging news, Cardiol Therapeutics has a profit margin of 0.0% and a negative return on equity of -174.0%. Investors should be cautious, as the company is still in the early stages of development and faces risks related to clinical trials and market acceptance.
Price Action Overview
This week, Cardiol Therapeutics Inc Class A (CRDL.TO) closed at C$1.92, reflecting a weekly increase of 7.32%. The stock has shown consistent upward momentum, gaining 15.03% over the past month and 29.41% year-to-date.
Recent Catalysts
Advertisement
While there have been no major announcements this week, Cardiol Therapeutics recently gained attention due to the publication of its Phase II MAvERIC study results in the Journal of the American Heart Association. The study demonstrated that CardiolRx™ significantly reduced pain and inflammation associated with recurrent pericarditis, which could strengthen the company's market position.
Technical Picture
From a technical standpoint, Cardiol Therapeutics is trading above both its 50-day moving average (C$1.60) and its 200-day moving average (C$1.55), indicating a positive trend. The stock is currently priced at 63% of its 52-week range, which spans from C$1.23 to C$2.33. With a beta of 0.51, the stock shows lower volatility compared to the market, which may appeal to conservative investors.
Insider Activity
No recent insider activity has been reported for Cardiol Therapeutics, which can be an important indicator of management confidence in the company’s future performance.
Conclusion
Cardiol Therapeutics Inc Class A closed at C$1.92, with a stable performance reflecting a 7.32% increase this week. As the company continues to advance its clinical studies and engage in industry discussions, investors will be watching closely for further developments.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
